Video

Jim McDermott from AstraZeneca: AstraZeneca Presents Full Slate of Studies at ADA

Author(s):

With more than 60 presentations at the American Diabetes Association's meeting AstraZeneca showed a wide range of studies all geared towards helping patients with this condition.

With more than 60 presentations at the American Diabetes Association's meeting AstraZeneca showed a wide range of studies all geared towards helping patients with this condition.

Jim McDermott, US Medical Lead for diabetes at AstraZeneca discussed some of the highlights from these presentations during the New Orleans meeting. McDermott cited several of the medications the company has in the field as well as work being done to improve care in the future as well.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.